Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	11,090	11,020	9,869	8,931	7,573	6,203
Other Revenue	10	-	-	-	1	2.9
Revenue	11,100	11,020	9,869	8,931	7,574	6,206
Revenue Growth (YoY)	8.98%	11.66%	10.51%	17.91%	22.06%	49.08%
Cost of Revenue	5,207	4,996	4,425	3,608	2,842	2,381
Gross Profit	5,893	6,024	5,444	5,323	4,732	3,825
Selling, General & Admin	1,485	1,432	1,137	944.7	840.1	770.5
Operating Expenses	1,485	1,432	1,137	944.7	840.1	770.5
Operating Income	4,408	4,593	4,308	4,378	3,892	3,054
Interest Expense	-23.2	-30.6	-44.1	-54.8	-61.5	-58.2
Interest & Investment Income	537.8	598.1	614.7	144.6	4.9	22.2
Currency Exchange Gain (Loss)	-26.1	-27.3	-24.6	-15.1	-13.9	-16.1
Other Non Operating Income (Expenses)	-24.6	-49.3	9.3	-0.6	1.7	0.8
EBT Excluding Unusual Items	4,871	5,084	4,863	4,453	3,824	3,003
Merger & Restructuring Charges	-197.6	-197.6	-	-	-	-
Gain (Loss) on Sale of Investments	-21.8	-9.5	-7.5	-149.1	17.1	311.9
Asset Writedown	-379	-	-	-13	-	-
Other Unusual Items	-1.8	0.5	51.6	57.5	3.1	-13.1
Pretax Income	-300.2	248.5	4,380	4,232	2,730	3,117
Income Tax Expense	688.7	784.1	760.2	910.4	388.3	405.2
Earnings From Continuing Operations	-988.9	-535.6	3,620	3,322	2,342	2,712
Net Income to Company	-988.9	-535.6	3,620	3,322	2,342	2,712
Net Income	-988.9	-535.6	3,620	3,322	2,342	2,712
Net Income to Common	-988.9	-535.6	3,620	3,322	2,342	2,712
Net Income Growth	-	-	8.96%	41.84%	-13.63%	130.43%
Shares Outstanding (Basic)	258	258	258	256	258	260
Shares Outstanding (Diluted)	258	258	261	259	260	263
Shares Change (YoY)	-1.20%	-1.00%	0.54%	-0.31%	-1.33%	1.04%
EPS (Basic)	-3.84	-2.08	14.05	12.97	9.09	10.44
EPS (Diluted)	-3.84	-2.08	13.89	12.82	9.01	10.29
EPS Growth	-	-	8.35%	42.29%	-12.44%	128.16%
Free Cash Flow	-1,250	-790.3	3,337	3,925	2,409	2,994
Free Cash Flow Per Share	-4.85	-3.06	12.81	15.15	9.27	11.37
Gross Margin	53.09%	54.67%	55.16%	59.60%	62.48%	61.63%
Operating Margin	39.71%	41.68%	43.65%	49.03%	51.39%	49.21%
Profit Margin	-8.91%	-4.86%	36.68%	37.20%	30.92%	43.70%
Free Cash Flow Margin	-11.26%	-7.17%	33.81%	43.95%	31.80%	48.24%
EBITDA	4,584	4,775	4,477	4,527	4,018	3,164
EBITDA Margin	41.30%	43.33%	45.36%	50.69%	53.05%	50.98%
D&A For EBITDA	176.9	182	169.5	148.3	125.6	109.5
EBIT	4,408	4,593	4,308	4,378	3,892	3,054
EBIT Margin	39.71%	41.68%	43.65%	49.03%	51.39%	49.21%
Effective Tax Rate	-	315.53%	17.36%	21.51%	14.22%	13.00%
Revenue as Reported	79.6	-	-	-	7,574	6,206

Updated May 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q